OakChart

Nkarta Inc

NKTXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.48+0.13 (9.63%)
2026-11-12 02:30 CET
Market cap
96.80 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-128.94 USD m
Free cash flow, TTM
-102.31 USD m
EPS diluted, TTM
-1.73
P/E
-
Compare

Price

NKTX against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.004.7M9.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NKTXclose 1.4820-day 1.6750-day 2.26200-day 2.511.4852w high52w low

60.2% under the 52-week high of 3.72 on 9 Jul 2026. 52-week low 1.13 on 9 Nov 2026. Last 15 sessions, 66.3% high to low

Volume 1.23× normal · the line is the 50-bar volume average

Profile

NKTX
52-week range, 14% of the way up
1.133.72

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

IndexRUT
Employees108
IPOJul 10, 2020
Beta1.27
ATR, 14d0.19
Rel volume1.23
Short float6.66%
Insider own19.62%
Inst own63.81%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap106.12M
Enterprise Value21.55M
Income-128.94M
Sales0.00M
Book/sh3.01
Cash/sh2.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees108
IPOJul 10, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.49
P/C0.68
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.79
Current Ratio5.79
Debt/Eq0.33
LT Debt/Eq0.30
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.73
EPS next Y-1.40
EPS next Q-0.41
EPS this Y-22.34%
EPS next Y18.73%
EPS next 5Y6.28%
EPS past 3/5Y18.61% 23.69%
Sales past 3/5Y- -
EPS Y/Y TTM-24.79%
Sales Y/Y TTM-
EPS Q/Q-52.18%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.-13.92% -

Ownership

Insider Own19.62%
Insider Trans-0.01%
Inst Own63.81%
Inst Trans2.29%
ROA-35.05%
ROE-46.58%
ROIC-46.00%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-11.56%
SMA50-34.65%
SMA200-40.95%
Trades-

Technical

Shs Outstand71.70M
Shs Float57.63M
Short Float6.66%
Short Ratio4.08
Short Interest3.84M
52W High3.72 -60.22%
52W Low1.13 30.97%
Volatility19.85% 10.46%
ATR (14)0.19
RSI (14)36.67
Beta1.27
Rel Volume1.23
Avg Volume941.69K
Volume1,157,979

Performance

Perf Week-14.45%
Perf Month-29.52%
Perf Quarter-35.65%
Perf Half Y-51.63%
Perf YTD-20.00%
Perf Year-26.37%
Perf 3Y-27.09%
Perf 5Y-91.94%
Perf 10Y-
Recom1.00
Target Price10.50
Prev Close1.35
Price1.48
Change %9.63%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Nov 02, 2026ResumedHH.C. WainwrightBuy$12+710.8%
Jun 23, 2026InitiatedTTD CowenBuy
May 15, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Oct 09, 2024InitiatedRRodman & RenshawBuy$14+845.9%
Aug 14, 2024UpgradeRRaymond JamesOutperform → Strong Buy$16+981.1%
Mar 22, 2024DowngradeRRaymond JamesStrong Buy → Outperform$13 → $16+981.1%
Dec 22, 2022DowngradeOOppenheimerOutperform → Perform
Oct 10, 2022InitiatedCCanaccord GenuityBuy$25+1,589.2%
Jul 28, 2022InitiatedNNeedhamBuy$26+1,656.8%
Jul 18, 2022InitiatedSSVB LeerinkOutperform$30+1,927.0%

Peers

Mkt cap
TickerCompanyMkt cap
ARTVArtiva Biotherapeutics Inc201.19M
FATEFate Therapeutics Inc195.12M
CABACabaletta Bio Inc312.79M
KYTXKyverna Therapeutics Inc316.63M
RNACCartesian Therapeutics Inc209.86M
IPSCCentury Therapeutics Inc315.07M
ALLOAllogene Therapeutics Inc311.85M
CRBUCaribou Biosciences Inc42.21M
CLLSCellectis ADR99.82M
SANASana Biotechnology Inc686.16M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HASTINGS PAUL JChief Executive OfficerJun 18 '26Sale2.711,7764,813390,247Jun 22 04:05 PM
HASTINGS PAUL JChief Executive OfficerJan 15 '26Sale2.0726,04653,915390,023Jan 20 05:39 PM
Mahmood NadirPresidentJan 15 '26Sale2.075,64911,693167,727Jan 20 05:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 100
  • Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 (GlobeNewswire) +9.63%
  • Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials (InvestorsHub) -8.09%
  • Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence (GlobeNewswire)
  • Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 (GlobeNewswire) +10.19%
  • Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.25%
  • Nkarta to Participate in September Investor Conferences (GlobeNewswire)
  • Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire) +10.62%
  • Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -5.28%
  • A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
  • Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
  • The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire)
  • Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire)
  • Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -6.71%
  • Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers (GlobeNewswire) +5.68% +15.70%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.450-0.395-0.4500.000.006
2026Q22026-08-10-0.540-0.360-0.5420.000.006
2026Q12026-05-12-0.370-0.354-0.3750.000.005
2025Q42026-03-25-0.370-0.310-0.3700.000.006
2025Q32025-11-10-0.290-0.305-0.2930.000.007
2025Q22025-08-12-0.310-0.355-0.3110.000.007
2025Q12025-05-14-0.430-0.426-0.4330.000.006
2024Q42025-03-26-0.350-0.405-0.3520.000.009
2024Q32024-11-07-0.390-0.368-0.3850.000.008
2024Q22024-08-13-0.340-0.472-0.3400.000.006
2024Q12024-05-09-0.580-0.545-0.5820.000.007
2023Q42024-03-21-0.570-0.581-0.5650.000.0010
2023Q32023-11-09-0.520-0.671-0.5230.000.0010
2023Q22023-08-10-0.680-0.653-0.6800.000.0010
2023Q12023-05-11-0.630-0.674-0.6300.000.0011
2022Q42023-03-16-0.670-0.616-0.6670.000.0012

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-5.440-4.347-5.4360.000.00
2021FY-2.620-2.714-2.6200.000.00
2022FY-2.610-2.534-2.6090.000.00
2023FY-2.400-2.375-2.3970.000.00
2024FY-1.600-1.658-1.6030.000.00
2025FY-1.410-1.307-1.4100.000.00
2026FY--1.725--0.00
2027FY--1.402--0.00
2028FY--1.161--4.33
2029FY--0.765--83.93
2030FY--0.789--102.23

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-063000.000.000.00
2026Q4S2026-08-213000.000.000.00
2026Q4S2026-08-114000.000.000.00
2026Q4S2026-06-224000.000.000.00
2026Q4S2026-05-133000.000.000.00
2026Q4S2026-04-103000.000.000.00
2026Q4S2026-03-264000.000.000.00
2026Q4S2026-02-183000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00

Estimate history

EPS, annual-0.008-0.648-5.436-2.62-2.609-2.397-1.603-1.407-1.7334
Period20182019202020212022202320242025TTM
EPS, quarterly-0.385-0.352-0.433-0.311-0.293-0.37-0.375-0.542-0.447
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual6.550.1150000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.52832.52832.62832.97148.87849.18170.64571.07971.704
Period20182019202020212022202320242025MRQ
Shares, quarterly70.56970.64570.95871.02571.02571.07971.2971.62271.704
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.126.55
Cost of Goods Sold Incl. D&A9.389.199.155.876.572.121.05--
Gross Profit-9.38-9.19-9.15-5.87-6.57-2.12-1.05--
Selling, General and Administrative Excl. Other139.41112.01119.04125.78112.3884.3150.4621.916.72
Research and Development99.3981.2487.5990.9088.2661.6635.4316.824.07
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-148.79-121.21-128.19-131.65-118.95-86.43-51.51-22.35-0.36
Interest Expense0.000.000.000.000.000.000.000.470.00
Unusual Expense-8.050.790.000.000.000.0040.16-1.420.00
Net Income Before Taxes-128.94-104.08-108.79-117.50-113.84-86.08-91.36-21.08-0.27
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-128.94-104.08-108.79-117.50-113.84-86.08-91.36-21.08-0.27
Net Income From Continuing Operations-128.94-104.08-108.79-117.50-113.84-86.08-91.36-21.08-0.27
Net Income-128.94-104.08-108.79-117.50-113.84-86.08-91.36-21.08-0.27
EPS (Recurring)-1.80-1.40-1.60-2.40-2.61-2.62-3.76-0.68-0.01
EPS (Basic, Before Extraordinaries)-1.73-1.41-1.60-2.40-2.61-2.62-5.44-0.65-0.01
EPS (Diluted)-1.73-1.41-1.60-2.40-2.61-2.62-5.44-0.65-0.01
EBITDA-139.41-112.01-119.04-125.78-112.38-84.31-50.46-21.80-0.17
Non-Operating Income (Expense)11.8117.9119.4014.155.120.350.310.320.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.438.5616.7317.2016.8614.466.750.950.18
Operating Margin--------19,368.66-5.44
Net Margin--------18,265.66-4.19
Shares Outstanding71.7071.0870.6549.1848.8832.9732.6332.5332.53
Market Capitalization96.8096.80175.72323.88292.39505.772,003.642,141.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.062.732.342.262.312.332.302.29
Gross Profit-2.06-2.73-2.34-2.26-2.31-2.33-2.30-2.29
Selling, General and Administrative Excl. Other33.7248.4428.5428.7024.9824.8634.2728.64
Research and Development27.4126.3122.6523.0217.8918.4521.8720.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-35.78-51.18-30.88-30.96-27.29-27.19-36.56-30.92
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.00-8.050.000.000.000.000.000.00
Net Income Before Taxes-33.33-40.37-27.83-27.41-21.71-22.98-31.98-25.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-33.33-40.37-27.83-27.41-21.71-22.98-31.98-25.93
Net Income From Continuing Operations-33.33-40.37-27.83-27.41-21.71-22.98-31.98-25.93
Net Income-33.33-40.37-27.83-27.41-21.71-22.98-31.98-25.93
EPS (Recurring)-0.45-0.62-0.37-0.37-0.29-0.31-0.43-0.35
EPS (Basic, Before Extraordinaries)-0.45-0.54-0.37-0.37-0.29-0.31-0.43-0.35
EPS (Diluted)-0.45-0.54-0.37-0.37-0.29-0.31-0.43-0.35
EBITDA-33.72-48.44-28.54-28.70-24.98-24.86-34.27-28.64
Non-Operating Income (Expense)2.452.763.043.555.574.214.584.99
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.761.861.901.901.772.052.833.89
Shares Outstanding71.7071.6271.2971.0871.0271.0270.9670.65
Market Capitalization96.80202.47150.42131.40147.02117.79130.56175.72

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments276.28267.35248.19352.14238.09314.9136.997.87
Short Term Receivables2.000.200.201.300.000.000.000.15
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets4.235.784.687.257.693.920.470.21
Total Current Assets282.51273.34253.07360.69245.78318.8337.478.23
Net Property, Plant & Equipment101.15110.67119.28107.6624.5317.8610.221.29
Total Investments and Advances18.85113.142.742.742.100.410.270.09
Intangible Assets-------0.00
Deferred Tax Assets13.08-------
Other Assets1.704.063.801.851.490.550.460.00
Total Assets417.29501.20378.88472.94273.90337.6548.419.61
Short Term Debt Incl. Current Port. of LT Debt6.896.056.074.252.481.401.520.00
Accounts Payable2.090.643.671.761.111.181.880.37
Income Tax Payable-------0.01
Other Current Liabilities13.2912.2313.6016.049.356.254.811.71
Total Current Liabilities22.2718.9223.3322.0512.948.838.212.08
Long Term Debt69.5374.2282.2778.699.977.5265.6012.71
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities13.08-------
Other Liabilities0.090.090.000.000.020.080.090.22
Total Liabilities104.9793.23105.60100.7322.9416.4373.8915.00
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity312.32407.98273.29372.21250.97321.22-25.48-5.40
Total Shareholders Equity312.32407.98273.29372.21250.97321.22-25.48-5.40
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity312.32407.98273.29372.21250.97321.22-25.48-5.40
Total Liabilities & Stockholders Equity417.29501.20378.88472.94273.90337.6548.419.61
Book Value Per Share4.395.785.567.627.619.84-0.78-0.17
Tangible Book Value Per Share4.395.785.567.627.619.84-0.78-0.17
Full-Time Employees10815715016313695--
Price to Book Ratio0.450.411.090.732.026.246.39-
Return on Assets-22.66-24.72-27.59-30.48-28.15-47.33-72.65-
Return on Equity-28.90-31.94-36.41-36.53-30.09-61.79--
Return on Invested Capital-27.26-22.56-33.05-25.25-32.99-27.79-52.54-3.75
Quick Ratio12.6914.4510.8516.3618.9936.104.563.96
Current Ratio12.6914.4510.8516.3618.9936.104.563.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-128.94-104.08-108.79-117.50-113.84-86.08-91.36-21.08-0.27
Depreciation9.389.199.155.876.572.121.050.550.18
Other Funds (Non Cash)15.176.6312.1114.5516.5317.6747.63-0.020.18
Funds from Operations-104.38-88.26-87.53-97.08-90.74-66.28-42.68-20.550.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.47-0.43-12.1610.9333.74-1.64-0.832.18-5.28
Cash from Operating Activities-99.91-88.70-99.70-86.16-57.00-67.93-43.51-18.37-5.18
Capital Expenditures-2.40-1.21-4.41-28.15-47.11-5.03-7.51-1.93-0.76
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.100.000.000.000.000.000.000.000.00
Purchase or Sale of Investments89.56101.53-125.15107.16-137.5837.56-202.57-16.370.00
Purchase of Investments-197.72-238.56-406.38-260.23-385.89-227.28-222.57-16.370.00
Sale Or Maturity of Investments287.27340.09281.23367.39248.31264.8420.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities87.26100.32-129.5679.02-184.6932.53-210.08-18.30-0.76
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.890.14226.080.69219.011.20329.820.050.09
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.890.14226.080.69219.011.20329.820.050.09
Proceedsfrom Stock Options0.140.14225.420.53217.62-0.28329.420.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.0049.530.00
Change in Long Term Debt0.000.000.000.000.000.000.005.990.00
Issuance of Long Term Debt0.000.000.000.000.000.000.005.990.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.890.14226.080.69219.011.20329.8249.580.09
Net Change in Cash-11.7611.76-3.17-6.45-22.68-34.1976.2312.92-5.85
Free Cash Flow-102.31-89.91-104.11-114.31-104.11-72.95-51.02-20.30-5.94
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments156.61182.76230.43276.28282.33289.69
Short Term Receivables1.402.101.702.002.102.20
Inventories0.000.000.000.000.000.00
Other Current Assets4.543.183.764.234.844.68
Total Current Assets162.55188.04235.88282.51289.27296.57
Net Property, Plant & Equipment85.0987.7198.30101.15101.98105.42
Total Investments and Advances59.4260.4136.3118.8534.1644.35
Deferred Tax Assets---13.08--
Other Assets1.401.481.571.701.821.97
Total Assets308.46337.64372.07417.29427.24448.31
Short Term Debt Incl. Current Port. of LT Debt7.487.287.086.896.376.91
Accounts Payable6.833.821.592.091.441.51
Other Current Liabilities13.7612.469.5413.2911.1810.51
Total Current Liabilities28.0723.5618.2122.2718.9918.93
Long Term Debt64.5566.2667.9269.5370.2671.63
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---13.08--
Other Liabilities0.090.090.090.090.090.09
Total Liabilities92.7189.9186.21104.9789.3490.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity215.75247.74285.86312.32337.90357.67
Total Shareholders Equity215.75247.74285.86312.32337.90357.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity215.75247.74285.86312.32337.90357.67
Total Liabilities & Stockholders Equity308.46337.64372.07417.29427.24448.31
Book Value Per Share3.013.464.014.394.765.04
Tangible Book Value Per Share3.013.464.014.394.765.04
Full-Time Employees103106-108-110
Price to Book Ratio0.450.710.480.390.410.31
Return on Assets-35.05-29.86-23.72-22.66-21.39-21.80
Return on Equity-46.58-38.76-30.07-28.90-26.69-26.94
Return on Invested Capital-11.89-12.86-7.87-7.18-5.32-5.35
Quick Ratio5.797.9812.9612.6915.2315.67
Current Ratio5.797.9812.9612.6915.2315.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-33.33-40.37-27.83-27.41-21.71-22.98
Depreciation2.062.732.342.262.312.33
Other Funds (Non Cash)1.9510.011.691.522.091.27
Funds from Operations-29.32-27.62-23.80-23.64-17.32-19.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.483.40-4.401.99-1.370.63
Cash from Operating Activities-25.84-24.22-28.20-21.65-18.69-18.75
Capital Expenditures-1.25-0.18-0.41-0.560.01-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.100.000.000.000.000.00
Purchase or Sale of Investments50.2321.3316.331.6625.3819.63
Purchase of Investments-9.66-42.36-54.28-91.42-57.78-68.79
Sale Or Maturity of Investments59.9063.7070.6193.0883.1688.42
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities49.0921.1515.911.1025.3919.49
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.140.680.010.060.000.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.140.680.010.060.000.08
Proceedsfrom Stock Options0.000.070.000.060.000.08
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.140.680.010.060.000.08
Net Change in Cash23.40-2.40-12.28-20.486.700.82
Free Cash Flow-27.08-24.41-28.61-22.21-18.68-18.89

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.66%3.8M57.6M739.83K
2026-10-155.95%3.4M57.6M616.97K
2026-09-306.36%3.7M57.6M661.29K
2026-09-156.09%3.5M57.6M668.99K
2026-08-316.28%3.4M54.7M651.05K
2026-08-146.58%3.6M54.7M659.16K
2026-07-316.13%3.3M54.3M708.44K
2026-07-155.90%3.2M54.3M841.34K
2026-06-306.23%3.4M54.3M764.62K
2026-06-156.37%3.5M54.3M749.04K
2026-05-299.64%5.2M54.2M785.04K
2026-05-159.52%5.2M54.2M820.60K
2026-04-309.76%5.3M54.1M787.73K
2026-04-1510.04%5.4M53.9M712.68K
2026-03-3110.28%5.5M53.8M755.51K
2026-03-1310.29%5.5M53.6M771.19K
2026-02-2710.93%5.9M53.6M754.76K
2026-02-1312.07%6.5M53.6M736.54K
2026-01-3011.52%6.5M56.7M748.66K
2026-01-1511.96%6.8M56.7M781.06K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.352.8672,7760.000.171-0.0100.001
call5.000.000.050.054.9863,3470.000.119-0.0130.000
call7.500.000.050.106.0747520.000.110-0.0130.000
put2.500.701.450.987.3941780.00-0.829-0.0090.001
put5.003.103.703.637.0851010.00-0.881-0.0120.000
put7.505.606.600.0012.8470.000.00-0.895-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-05-19SCHEDULE 13D/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-03EFFECTEffectiveness filing by commission orderSEC
2026-04-03424B5SEC
2026-04-01CORRESPSEC
2026-03-31UPLOADUpload SubmissionSEC
2026-03-268-KCurrent report2026-03-25SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-03-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06004.81K1
2026-050000
2026-040000
2026-030000
2026-020000
2026-010065.61K2
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.15.10%
BlackRock, Inc.8.81%
NEA Management Company, LLC4.99%
Samsara BioCapital, LLC4.90%
SR ONE CAPITAL MANAGEMENT, LP4.66%
GSK plc4.40%
VANGUARD CAPITAL MANAGEMENT LLC3.11%
Monaco Asset Management SAM3.05%
CITADEL ADVISORS LLC3.04%
TWO SIGMA INVESTMENTS, LP2.62%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.19%
iShares Russell 2000 ETF1.60%
Wasatch Micro Cap Fund1.22%
Wasatch Ultra Growth Fund0.99%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Fidelity Small Cap Index Fund0.69%
iShares Russell 2000 Value ETF0.64%
College Retirement Equities Fund - Total Global Stock Account0.49%
Fidelity Extended Market Index Fund0.41%
T. Rowe Price Small-Cap Value Fund, Inc.0.37%

OakChart. NKTX. Cached 15 minutes.